Decentralized clinical trials (DCTs) are clinical studies designed so that some or all activities happen outside a traditional research hospital or clinic. Instead of requiring participants to travel repeatedly to a specific site, these trials bring the study to the participant, using tools like telemedicine visits, wearable sensors, and home drug delivery. The concept has gained serious traction in recent years, with the global DCT market projected to reach $10.4 billion in 2026 and grow to $15.45 billion by 2032.
How Decentralized Trials Work
In a traditional clinical trial, nearly everything happens at a designated research site. You show up for screening, consent, lab work, treatment, and follow-up visits, sometimes over months or years. That model works, but it also creates a major bottleneck: only people who live near a site, have flexible schedules, and can manage frequent travel are likely to participate.
Decentralized trials shift some or all of those activities to wherever the participant happens to be. That could mean your living room, a nearby pharmacy, or a local doctor’s office. The data still flows back to the research team, but the physical demands on you are dramatically reduced.
There are two main flavors. A fully decentralized trial conducts every activity remotely. You might consent through an online platform, receive medication by mail, track your health with a wearable device, and check in with the study team via video call. A hybrid trial mixes both approaches: you might visit a traditional site for an initial physical exam or a blood draw, then complete everything else from home. Hybrid models are far more common right now because many trials still require at least some hands-on clinical assessments that can’t be done remotely.
The Technology Behind Remote Trials
Running a trial outside a controlled clinical environment requires a stack of digital tools working together. The Trials@Home initiative, a large European proof-of-concept study, offers a practical look at what this involves. Participants in its fully remote arm used a Bluetooth-enabled glucometer to self-monitor blood sugar, a smart injector cap that tracked when and how they administered insulin (syncing data to a mobile app weekly), and an electronic consent platform integrated into a central system. Telemedicine visits replaced in-person check-ins.
More broadly, DCTs rely on electronic patient-reported outcome tools (ePRO), which are essentially digital questionnaires that let participants log symptoms, side effects, and quality-of-life measures from their phones. Electronic clinical outcome assessments (eCOA) serve a similar purpose for more structured measurements. Wearable sensors can passively collect data like heart rate, activity levels, or sleep patterns without the participant needing to do anything beyond wearing the device. All of these systems need to meet strict data standards. In the U.S., electronic records generated in a clinical trial must comply with FDA regulations governing digital record-keeping and electronic signatures.
What the Research Shows About Retention
The strongest case for decentralized trials is that participants are more likely to stick with the study once they enroll. Dropping out is a chronic problem in clinical research, and it can compromise the quality of results or force trials to run longer and cost more. Seven studies that tracked retention in decentralized designs reported positive outcomes, with four directly comparing decentralized methods to traditional ones. One study found 89% retention in its decentralized arm versus 60% in the conventional arm. Others reported retention rates of 87%, 92%, and 96% across various remote trial designs. The pattern is consistent: making participation easier keeps people enrolled.
Recruitment, however, is a more complicated picture. The RADIAL proof-of-concept trial targeted 300 participants for its fully decentralized arm but enrolled only eight. Its conventional and hybrid arm, using 32 traditional sites, enrolled 100 out of a target of 300. Both arms fell short, but the decentralized arm struggled significantly more. One telling detail: online recruitment methods like social media ads and search engine advertising generated plenty of clicks and website visits, but almost none of those converted into actual enrollees. The most effective strategy for the remote arm turned out to be direct invitations sent through existing research databases, which accounted for seven of the eight enrolled participants.
Impact on Participant Diversity
One promise of decentralized trials is broadening who participates in research. If you don’t need to live near an academic medical center, the thinking goes, trials could reach people in rural areas, people with disabilities, and communities historically underrepresented in research. There’s some evidence for this. One study comparing online and traditional recruitment found that the online-recruited group was more geographically diverse and included a higher percentage of women.
But there’s a meaningful counterweight. DCTs can introduce what researchers call the digital divide. People who are unfamiliar with smartphones, wearable devices, or video calls may feel discouraged from enrolling. Limited internet access, which disproportionately affects lower-income and rural populations, creates another barrier. A separate study comparing decentralized and traditional approaches on overall representativeness was inconclusive, finding that neither approach was clearly superior. The trial design shapes who shows up, and decentralized models simply shift which populations are easiest and hardest to reach.
Data Quality and Security Concerns
Moving trials out of controlled clinical settings introduces real questions about data integrity. When participants self-report symptoms or self-administer treatments at home, there’s more room for inconsistency. Protocols need to clearly describe the steps taken to minimize biases introduced by self-reporting, and ethics committees need to evaluate those measures before the trial begins.
Cybersecurity is another concern. Trials that rely on wearables, apps, and web-based interactions create distributed data networks with more potential entry points for breaches. Conventional trials have data security risks too, but the sheer number of connected devices in a DCT expands the attack surface. Best practice calls for state-of-the-art encryption whenever digital devices are used to verify participant identity, monitor medication use, or communicate side effects.
There’s also the question of whether investigators and ethics review boards are equipped to evaluate the novel risks that digital tools introduce. The types of threats to participant privacy in a data-heavy, app-driven trial may look very different from those in a traditional study, and conventional risk-benefit frameworks may not fully capture them.
Regulatory Status in the U.S. and Europe
The FDA issued its final guidance on decentralized trials in September 2024, titled “Conducting Clinical Trials With Decentralized Elements.” The document makes one thing clear upfront: the regulatory requirements for decentralized trials are the same as for traditional ones. There is no separate, lighter framework. Sponsors still need to ensure compliance with local laws governing medical practice and drug administration, and investigators can obtain informed consent remotely (electronically or on paper) as long as all existing regulatory requirements are met.
The guidance encourages sponsors to plan specifically for decentralized elements, including the use of local healthcare providers, local labs, home visits, and direct shipment of the investigational product to participants. It’s a practical roadmap rather than a set of new rules.
In Europe, the European Commission, Heads of Medicines Agencies, and European Medicines Agency jointly published recommendations to facilitate DCTs across EU and EEA countries. These include an overview of national provisions for specific decentralized trial elements, acknowledging that regulations vary country by country. The agencies describe this as a first step, expected to evolve as more experience accumulates.
Cost Considerations
It might seem intuitive that eliminating physical site visits would save money, but the economics are not straightforward. An analysis of data management costs across multiple clinical research networks found that decentralized data management models were actually more expensive than centralized ones. In one large study network, total data management costs were roughly $1.95 million for the centralized model, $3.45 million for a decentralized shared-database model, and $5.35 million for a decentralized local-software model. The cost gap narrowed when fewer local data centers were involved, but the decentralized approach remained pricier across all scenarios studied.
These figures reflect data infrastructure costs specifically, not the full picture. Decentralized trials may save money in other areas, such as reduced site overhead, fewer patient travel reimbursements, and faster enrollment timelines. But the technology stack required to run a remote trial, including platform integration, device provisioning, and ongoing technical support, represents a significant investment that can offset those savings.
Where Decentralized Trials Fit Best
Not every trial is a good candidate for decentralization. Studies that require complex imaging, surgical procedures, or close physical monitoring still need traditional sites. But trials focused on chronic conditions with well-established measurement tools, studies of oral medications, and research involving patient-reported outcomes are natural fits. The hybrid model, where the most critical assessments happen in person and routine data collection happens remotely, is emerging as the most practical approach for the majority of studies.
The market’s steady 6.6% annual growth rate signals that pharmaceutical companies and contract research organizations see DCTs as a permanent part of the landscape rather than a pandemic-era experiment. The infrastructure is still maturing, recruitment strategies need refinement, and regulatory frameworks across countries remain uneven. But the core value proposition, making it easier for real people to participate in the research that shapes their future treatments, is difficult to argue against.